Welcome to the ASM Global Research Symposium on the One Health Approach to Antimicrobial Resistance (AMR), hosted in partnership with the Centre for Infectious Disease Research (CIDR) at the Indian Institute of Science (IISc). As ASM’s first symposium in India—the second in the Global Research Symposium series—we bring together scientists, clinicians, policymakers and industry leaders from around the world. The symposium will take place in person at the AV Rama Rao Auditorium on the IISc campus in Bengaluru. By cultivating cross-sector partnerships and scientific innovation, the symposium will explore the connections between human, animal and environmental health, with a particular emphasis on AMR—one of the world’s most urgent health priorities.

Symposium Dates: Oct. 29-31, 2025

Registration for the symposium will open soon. Questions? Email pubsmktg@asmusa.org.

Emerging, drug-resistant pathogens are a growing health threat, demanding concerted efforts and sustainable solutions that are effective and accessible worldwide.

The 2025 ASM Global Research Symposium in India will bring together experts to discuss the evolution and mechanisms of AMR, AI-driven solutions, clinical case studies and diagnostics through the One Health approach that bridges human, animal and environmental health. The symposium aims to facilitate collaboration to accelerate practical strategies for combating AMR.

ASM is committed to advancing the microbial sciences through expert dialogue and knowledge sharing. This symposium serves as a platform to unite the global community in combating AMR. Read the press release about the India Global Research Symposium.

The Indian Institute of Science (IISc) in Bengaluru, founded in 1909, is one of India’s most respected research institutions. With a long history of scientific discovery and innovation, IISc has been instrumental in advancing microbial sciences and infectious disease research.

The Centre for Infectious Disease Research (CIDR) at IISc is committed to high-quality research on human pathogens by providing state-of-the-art laboratories, including a biosafety level 3 (BSL-3) facility and infrastructure. CIDR’s approach involves strong basic and translational research, implementation of clinical programs on infectious diseases, education and support to academic institutes and pharma companies. Research at CIDR focuses on Mycobacterium tuberculosis, human immunodeficiency virus (HIV), SARS-CoV-2, influenza, Zika and dengue viruses. With a continued focus on understanding infection biology and developing new treatment strategies, the centre also plays a key role in high-impact collaborative infectious disease research, training scientists and increasing public awareness of infectious diseases. Through its research and partnerships, CIDR is contributing to efforts to combat AMR. By integrating the One Health approach into these efforts, CIDR is helping shape strategies to tackle drug-resistant infections.